Faeth Therapeutics (4070) Ownership - Who Owns Faeth Therapeutics?
Faeth Therapeutics (4070) Ownership Overview
- 5.14% Insiders
- 0.80% Mutual Funds
- 0.32% Other Institutional Investors
- 5.40% ETFs
- 88.34% Public Companies and Individual Investors
The ownership structure of Faeth Therapeutics (DE:4070) stock is a mix of institutional, retail, and individual investors. Approximately 6.51% of the company’s stock is owned by Institutional Investors, 5.14% is owned by Insiders, and 88.34% is owned by Public Companies and Individual Investors.
The ownership structure of Faeth Therapeutics (DE:4070) stock is a mix of institutional, retail, and individual investors. Approximately 6.51% of the company’s stock is owned by Institutional Investors, 5.14% is owned by Insiders, and 88.34% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Jun 30, 2026 | Brian C Stephenson | $326,127 | |
| Jun 25, 2026 | Brian C Stephenson | $401,269 | |
| Jun 23, 2026 | Brian C Stephenson | $405,921 | |
| Jun 23, 2026 | Anand Kiran Parikh | $55,447 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Felix Baker | 1,286,411 | Institution | 4.98% | 23,417,826 |
| Vanguard | 928,912 | Institution | 3.59% | 16,909,914 |
| Anand Kiran Parikh | 817,699 | Insider | 3.16% | 14,885,393 |
| Peter Harwin | 722,020 | Institution | 2.79% | 13,143,652 |
| Peter Kolchinsky | 722,020 | Institution | 2.79% | 13,143,652 |
| Michael Rockefeller | 361,010 | Institution | 1.40% | 6,571,826 |
| Spdr | 224,016 | Institution | 0.87% | 4,077,987 |
| Franklin Strategic Series | 180,711 | Institution | 0.70% | 3,289,663 |
| Millennium Management Llc | 133,986 | Insider | 0.52% | 2,439,081 |
| Cambrian Biopharma Inc | 130,142 | Insider | 0.50% | 2,369,105 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Franklin Strategic Series | 180,711 | Institution | 0.70% | 3,289,663 |
| Fidelity Concord Street Trust | 12,759 | Institution | 0.05% | 232,265 |
| Vanguard Index Funds | 10,115 | Institution | 0.04% | 184,133 |
| Victory Portfolios Iii | 1,892 | Institution | <0.01% | 34,442 |
| John Hancock Variable Insurance Trust | 41 | Institution | <0.01% | 746 |
FAQ
Who Owns Faeth Therapeutics (DE:4070)?
According to the latest TipRanks data, approximately 6.51% of the company's stock is held by institutional investors, 5.14% is held by insiders, and 88.34% is held by public companies and individual investors.
What percentage of Faeth Therapeutics (DE:4070) stock is held by institutional investors?
According to the latest TipRanks data, approximately 6.51% of Faeth Therapeutics (DE:4070) stock is held by institutional investors: 0.80% by mutual funds, 5.40% by ETFs and 0.32% by other institutional investors.
What percentage of Faeth Therapeutics (DE:4070) stock is held by retail investors?
According to the latest TipRanks data, approximately 88.34% of Faeth Therapeutics (DE:4070) stock is held by public companies and individual investors.
Who owns the most shares of Faeth Therapeutics (DE:4070)?
Felix Baker owns the most shares of Faeth Therapeutics (DE:4070).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
